Because endometriosis impacts health-related quality of life, a study has assessed the validity and responsiveness of the Health-Related Productivity Questionnaire, version 2 (HRPQ) specifically for employment and household productivity. The post hoc analysis in the journal Expert Review of Pharmacoeconomics used data from the Elaris Endometriosis I and II clinical trials (EM-1 and EM-2), consisting of 871 women (mean age 31.5) and 815 women (mean age 33.2), respectively.
Participants in both trials were randomized in a 3:2:2 ratio to receive daily doses of either placebo, elagolix 150 mg once daily or elagolix 200 mg twice daily for 6 months.
Due to the potential affect that endometriosis has on a person’s health-related quality of life (HRQL), “measuring absenteeism and presenteeism for both paid employment and household chores simultaneously is imperative and should be included as an evaluation endpoint during clinical product development,” the authors wrote.
The self-reported, 9-item, 1-week recall HRPQ (version 2) used in the EM-I and EM-II trials revealed that the total hours of lost work among employed women were 16.5 and 15.2 per week, respectively, whereas the total hours of lost work among the household group were 8.3 and 8.4 per week, respectively. For employed women, absenteeism because of mild pain was 2.0 lost hours per week, from moderate pain 3.4 hours, and from severe pain 4.7 hours. Similarly, lost ability to work while on the job among employed women was 11.9, 13.5 and 16.4 lost hours per week, respectively.